| Literature DB >> 21480966 |
H Kahleova1, M Matoulek, H Malinska, O Oliyarnik, L Kazdova, T Neskudla, A Skoch, M Hajek, M Hill, M Kahle, T Pelikanova.
Abstract
AIMS: The aim of this study was to compare the effects of calorie-restricted vegetarian and conventional diabetic diets alone and in combination with exercise on insulin resistance, visceral fat and oxidative stress markers in subjects with Type 2 diabetes.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21480966 PMCID: PMC3427880 DOI: 10.1111/j.1464-5491.2010.03209.x
Source DB: PubMed Journal: Diabet Med ISSN: 0742-3071 Impact factor: 4.359
FIGURE 1Enrollment of the participants and completion of the study. T2DM, Type 2 diabetes mellitus.
Baseline characteristics of the study population
| Characteristic | Experimental group ( | Control group ( |
|---|---|---|
| Age (years) | 54.6 ± 7.8 | 57.7 ± 4.9 |
| Sex (%) | ||
| Male | 17 (46) | 18 (49) |
| Female | 20 (54) | 19 (51) |
| Smokers (%) | 9 (24) | 5 (14) |
| Weight (kg) | 101.1 ± 17.1 | 100.8 ± 17.8 |
| BMI (kg m−2) | 35.1 ± 6.1 | 35.0 ± 4.6 |
| Waist circumference (cm) | 113.7 ± 11.2 | 113.8 ± 13.1 |
| Blood pressure (mmHg) | ||
| Systolic | 133 ± 16 | 130 ± 13 |
| Diastolic | 85 ± 13 | 84 ± 8 |
| Resting heart rate (beats min−1) | 73 ± 7 | 74 ± 10 |
| Volume of abdominal fat (ml) | ||
| Visceral fat | 4266 ± 1994 | 4275 ± 1954 |
| Subcutaneous fat | 8140 ± 3847 | 8110 ± 2739 |
| Metabolic clearance rate of glucose (ml kg−1 min−1) | 2.29 ± 0.8 | 2.24 ± 0.8 |
| Blood biomarkers | ||
| Cholesterol total (mmol l−1) | 4.4 ± 0.8 | 4.2 ± 0.9 |
| LDL cholesterol (mmol l−1) | 2.54 ± 0.6 | 2.57 ± 0.8 |
| HDL cholesterol (mmol l−1) | 1.07 ± 0.3 | 1.09 ± 0.2 |
| Triglycerides (mmol l−1) | 2.1 ± 0.9 | 2.1 ± 0.9 |
| Homocysteine (μmol l−1) | 12.5 ± 4.5 | 13.1 ± 3.7 |
| Free fatty acids (mmol l−1) | 0.54 ± 0.3 | 0.58 ± 0.4 |
| Fibrinogen (g l−1) | 4.3 ± 1.3 | 3.9 ± 1.1 |
| Fasting plasma immunoreactive insulin (nmol l−1) | 15.4 ± 8.0 | 14.8 ± 9.3 |
| Fasting plasma C-peptide (mIU l−1) | 1.3 ± 0.6 | 1.4 ± 0.6 |
| Fasting plasma glucose (mmol l−1) | 9.5 ± 2.8 | 9.5 ± 2.4 |
| HbA1c [DCCT, %; (IFCC, mmol/mol)] | 7.6 ± 1.4 (60 ± 14) | 7.7 ± 1.2 (61 ± 12) |
| hsCRP (mg l−1) | 5.6 ± 6.3 | 5.5 ± 4.8 |
| Adiponectin total (μg ml−1) | 6.7 ± 3.8 | 6.8 ± 3.1 |
| HMW adiponectin (μg ml−1) | 4.0 ± 2.0 | 4.0 ± 2.6 |
| Leptin (p | 1100 ± 1121 | 1112 ± 946 |
| Resistin (ng ml−1) | 9.47 ± 5.8 | 9.82 ± 4.6 |
| Vitamin C (μg mmol−1) | 80.7 ± 22.0 | 81.3 ± 24.2 |
| Superoxide dismutase (U ml−1) | 4.7 ± 2.2 | 4.7 ± 1.1 |
| Catalase (H2O2.min−1 mg−1) | 679 ± 189 | 659 ± 198 |
| TBARS (μmol l−1) | 1.7 ± 0.6 | 1.7 ± 0.4 |
| Reduced glutathione (mmol l−1) | 2.7 ± 0.9 | 2.7 ± 0.6 |
| Glutathione reductase (mmol NADPH min−1 mg−1) | 259 ± 97 | 262 ± 94 |
| Glutathione peroxidase (mmol GSH min−1 mg−1) | 631 ± 147 | 627 ± 125 |
| Glutathione transferase (mmol GSH min−1 mg−1) | 32.2 ± 11.5 | 34.1 ± 9.1 |
| Medications | ||
| Oral hypoglycaemic agents (%) | ||
| Metformin | 29 (78) | 28 (76) |
| Sulphonylurea | 20 (54) | 13 (35) |
| Thiazolidinedione | 7 (19) | 5 (14) |
| Other | 8 (22) | 3 (8) |
| Lipid-lowering therapy (%) | 22 (59) | 16 (43) |
| Anti-hypertensive therapy (%) | 25 (68) | 22 (59) |
| Indirect calorimetry | ||
| Respiratory quotient | 0.77 ± 0.1 | 0.76 ± 0.1 |
| Resting energy expenditure (REE) (kcal day−1) | 1792 ± 317 | 1727 ± 322 |
| REE (% of predicted value) | 111.9 ± 49.4 | 106.5 ± 35 |
| Fasting oxidation of carbohydrates (mg kg−1 min−1) | 0.73 ± 0.66 | 0.73 ± 0.66 |
| Fasting oxidation of fat (mg kg−1 min−1) | 0.71 ± 0.25 | 0.72 ± 0.4 |
| Fasting oxidation of protein (mg kg−1 min−1) | 0.73 ± 0.33 | 0.73 ± 0.15 |
| Dietary intake | ||
| Caloric intake (kcal day−1) | 1835 ± 473 | 1832 ± 655 |
| Carbohydrates (% of daily energy) | 41.7 ± 7.58 | 42.3 ± 8.23 |
| Fats (% of daily energy) | 37.94 ± 6.46 | 37.89 ± 6.53 |
| Proteins (% of daily energy) | 20.55 ± 4.66 | 18.42 ± 3.31 |
| Fibre intake (g day−1) | 22.87 ± 7.06 | 22.95 ± 6.51 |
| P/S ratio | 0.69 ± 0.28 | 0.53 ± 0.19 |
| Cholesterol intake (mg day−1) | 386 ± 181 | 381 ± 224 |
| Quality of life | ||
| OWLQOL score | 44.85 ± 23.69 | 40 ± 20.4 |
| WRSM score | 32.29 ± 26.18 | 30.77 ± 18.16 |
Data are means ± sd.
DCCT, Diabetes Control and Complications Trial; GSH, glutathione; H2O2, hydrogen peroxide; HMW, high molecular weight; hsCRP, high-sensitivity C-reactive protein; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; NADPH, nicotinamide adenine dinucleotide phosphate; OWLQOL, Obesity and Weight-Loss Quality-of-Life; P/S ratio, ratio of polyunsaturated to saturated fatty acids; TBARS, thiobarbituric acid reactive substances; WRSM, Weight-Related Symptoms.
Changes in clinical and laboratory variables during the study
| Experimental group | Control group | ||||
|---|---|---|---|---|---|
| Change 3–0 | Change 6–0 | Change 3–0 | Change 6–0 | ||
| BMI (kg m−2) | –2.15 ± 1.42‡ | –2.18 ± 2.06‡ | –1.21 ± 1.46‡ | –0.98 ± 1.57‡ | 0.001 |
| Total cholesterol (mmol l−1) | –0.04 ± 0.74 | –0.11 ± 0.81 | 0.13 ± 0.51 | –0.04 ± 0.76 | 0.730 |
| HDL cholesterol (mmol l−1) | –0.05 ± 0.18 | –0.01 ± 0.14 | 0.07 ± 0.16 | 0.08 ± 0.14* | 0.070 |
| LDL cholesterol (mmol l−1) | –0.2 ± 0.57* | –0.17 ± 0.68* | –0.16 ± 0.48 | –0.14 ± 0.68 | 0.050 |
| Homocysteine (μmol l−1) | –2.9 ± 2.97‡ | –4.62 ± 3.4‡ | –1.49 ± 3.09* | –3.01 ± 2.92‡ | 0.170 |
| Triglycerides (mmol l−1) | –0.11 ± 0.96 | –0.27 ± 0.92 | 0.03 ± 0.49 | 0.05 ± 0.63 | 0.120 |
| Free fatty acids (mmol l−1) | –0.09 ± 0.38 | 0.09 ± 0.66 | 0.04 ± 0.72 | 0.24 ± 0.52* | 0.140 |
| Fibrinogen | –0.05 ± 1.36 | –0.51 ± 1.1* | 0.09 ± 0.75 | –0.33 ± 0.79* | 0.490 |
| Fasting plasma glucose (mmol l−1) | –1.45 ± 2.2‡ | –1.49 ± 2.03‡ | –1.45 ± 2.83† | –1.05 ± 3.2 | 0.420 |
| Fasting plasma insulin (nmol l−1) | –2.85 ± 7.52* | –4.07 ± 9.12‡ | –1.92 ± 8.27 | –2.93 ± 8.75 | 0.780 |
| Fasting plasma C-peptide (mIU l−1) | –0.1 ± 0.37 | –0.18 ± 0.46 | –0.21 ± 0.34‡ | 0 ± 1.08 | 0.750 |
| HbA1c (DCCT, %) HbA1c (IFCC, mmol/mol) | –0.68 ± 0.86‡ –7 ± 9‡ | –0.65 ± 0.99‡ –7 ± 10‡ | –0.59 ± 0.89‡ –6 ± 9‡ | –0.21 ± 1.1 –2 ± 11 | 0.370 |
| hsCRP (mg l−1) | –1.68 ± 3.61* | –2.27 ± 4.69* | –1.41 ± 4.53 | 0.09 ± 7.4 | 0.450 |
| HMW adiponectin (μg ml−1) | 0.09 ± 1.41 | 0.59 ± 1.23* | 0.54 ± 1.44 | 0.33 ± 1.49 | 0.050 |
| Catalase (H2O2 min−1 mg−1) | 282 ± 290‡ | 203 ± 237‡ | 185 ± 237‡ | 118 ± 224† | 0.130 |
| TBARS (μmol l−1) | –0.31 ± 0.53† | –0.66 ± 0.54‡ | 0.27 ± 0.63* | –0.56 ± 0.62‡ | 0.560 |
| Dietary intake | |||||
| Caloric intake (kcal day−1) | –137 ± 477‡ | –99 ± 438‡ | –128 ± 641‡ | –36.9 ± 837‡ | 0.13 |
| Carbohydrates (% of daily energy) | 5.07 ± 9.81* | 8.24 ± 10.22† | –0.32 ± 9.21 | 3.15 ± 6.78 | 0.080 |
| Fats (% of daily energy) | 1.95 ± 2.63 | –1.22 ± 7.05* | 6.2 ± 2.77 | –1.33 ± 5.13* | 0.610 |
| Proteins (% of daily energy) | –6.87 ± 4.52‡ | –4.36 ± 3.05‡ | 0.52 ± 4.29 | –0.23 ± 4.12 | < 0.001 |
| Fibre intake (g day−1) | 6.02 ± 9.58* | 2.57 ± 6.62 | 1.73 ± 9.89 | –1.82 ± 8.87 | 0.030 |
| P/S ratio | 0.74 ± 0.55‡ | 0.57 ± 0.34‡ | 0.14 ± 0.22* | 0.1 ± 0.36 | 0.004 |
| Cholesterol intake (mg day−1) | –322 ± 224‡ | –319 ± 206‡ | –55.6 ± 187 | –22.2 ± 222 | < 0.001 |
| Quality of life | |||||
| OWLQOL score | 5.1 ± 12* | 11.5 ± 16‡ | 6.5 ± 12.7* | 7.3 ± 14.9* | 0.010 |
| WRSM score | –9.9 ± 14.8‡ | –13 ± 20.8‡ | –8.1 ± 16.9* | –8.8 ± 17.5* | 0.400 |
Data are means ± sd.
Listed P-values are for interaction between group and time assessed by repeated measures ANOVA. *P < 0.05, †P < 0.01 and ‡P < 0.001 for within-group changes from baseline assessed by paired comparison t-tests.
DCCT, Diabetes Control and Complications Trial; H2O2, hydrogen peroxide; HMW, high molecular weight; hsCRP, high-sensitivity C-reactive protein; IFCC, International Federation of Clinical Chemistry and Laboratory Medicine; OWLQOL, Obesity and Weight-Loss Quality-of-Life; P/S ratio, ratio of polyunsaturated to saturated fatty acids; TBARS, thiobarbituric acid reactive substances; WRSM, Weight-Related Symptoms.
FIGURE 2Anthropometric variables, LDL cholesterol, insulin sensitivity, resting energy expenditure and Beck score during the study. Experimental group: closed circles/solid line; control group: open circles/dashed line. Error bars represent 95% CIs. P-values for interaction between group and time assessed by repeated measures ANOVA are P < 0.001 for weight (a), P < 0.001 for waist circumference (b), P = 0.05 for LDL cholesterol (c), P = 0.02 for subcutaneous fat (d)*, p = 0.007 for visceral fat (e)*, P = 0.04 for metabolic clearance rate of glucose (MCR) (f)†. *Magnetic resonance imaging data were not complete in 15 out of the 74 participants: 8/37 in the experimental group (six because of dropout, two as a result of claustrophobia during the first examination) and 7/37 in the control group (six because of dropout, one as a result of claustrophobia during the first examination). †Data from the hyperinsulinaemic isoglycaemic clamp were not complete in 19 out of the 74 participants: 9/37 in the experimental group (six because of dropout, three as a result of patients’ fragile veins) and 10/37 in the control group (six because of dropout, four as a result of patients’ fragile veins).
FIGURE 3Plasma levels of oxidative stress markers and adipokines during the study. Experimental group: closed circles/solid line; control group: open circles/dashed line. Error bars represent 95% CIs. P-values for interaction between group and time assessed by repeated measures ANOVA are P = 0.002 for Vitamin C (a), P < 0.001 for superoxide dismutase (b), P < 0.001 for reduced glutathione (c), P < 0.001 for glutathione reductase (d), P = 0.004 for glutathione peroxidase (e), P = 0.003 for glutathione transferase (f), P = 0.02 for adiponectin (g), P = 0.005 for resistin (h) and P = 0.05 for leptin (i). GSH, glutathione; NADPH, nicotinamide adenine dinucleotide phosphate.